L2M – Advancing Cancer Immunotherapies Through Microbiome-Derived Solutions

We are dedicated to enhancing cancer treatment by leveraging the microbiome’s potential – the diverse microorganisms within our bodies. While existing therapies like immune checkpoint blockade (ICB) show promise, their effectiveness varies widely among patients. Our project focuses on the translation of innovative microbiome-derived compounds from laboratory to the market to improve ICB therapy outcomes. By deciphering the microbiome’s impact on treatment response, we are crafting solutions that benefit more patients, even those undergoing antibiotic treatment. Through our partnership with University Technology International, we are fast-tracking the translation of these compounds from lab discovery to market availability. Our work not only addresses a critical need in immunotherapy but also enriches our partner’s understanding of the market landscape, paving the way for impactful advancements in cancer treatment.

Faculty Supervisor:

Douglas Mahoney

Student:

Partner:

Innovate Calgary

Discipline:

Life Sciences

Sector:

Professional, scientific and technical services

University:

University of Calgary

Program: